Kidney Week 2026: Three IgA Nephropathy Drugs Show Strong Phase III Results
Start here
At ASN Kidney Week 2026, three Phase III trials in IgA nephropathy delivered promising results. Atacicept's ORIGIN 3 interim analysis met its primary endpoint and secured FDA accelerated approval, with two-year data showing eGFR stabilization and a significant reduction in the risk of disease progression. Sibeprenlimab's VISIONARY trial reduced the risk of kidney function loss or kidney failure by 97% versus placebo at two years. Telitacicept's TELIGAN two-year data confirmed durable kidney protection in high-risk patients with a good safety profile. Open questions include longer-term outcomes, full approvals beyond atacicept's accelerated nod, and how the three therapies will compare in practice.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- medicalxpress.comPickClinical trials generate promising results for improving kidney health
Three Phase III IgA nephropathy trials were presented at ASN Kidney Week 2026. Atacicept's ORIGIN 3 interim analysis met its primary endpoint and secured FDA accelerated approval, with two-year data showing stabilized eGFR and a markedly reduced progression risk. Sibeprenlimab's VISIONARY trial showed a 97% reduction versus placebo in the risk of kidney function loss or kidney failure over two years, and telitacicept's TELIGAN two-year data confirmed durable kidney protection with a good safety profile in high-risk patients.
Heat trend for this story
Heat now 5·Peak in the comparable set 10 (Oct 22 19:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.